Latest News

ExoProTher's groundbreaking approach to cancer treatment has gained well-deserved recognition with a featured article on NoCamels, a leading source of Israeli innovative technology and science news. Titled "Revolutionary Protein-Based Cancer Drug Targets Tumors Without Harming Healthy Cells," the article highlights ExoProTher's achievement in developing a protein-based cancer drug that demonstrates an exceptional ability to selectively target cancerous cells while sparing healthy ones.
The featured interview with Lana Volokh, CEO and Alex Tendler, CTO of ExoProTher’s presents our unique approach to cancer therapy.
The article further highlights ExoProTher's commitment to revolutionizing cancer therapy and impacting cancer patients' lives.

ExoProTher's CTO Presents Breakthrough Finding on Chicken p53 Efficacy Against Human Cancers
Orlando, Florida — April 19, 2023 — Dr. Alex Tendler, Chief Technology Officer of ExoProTher Medical, participated in the AACR Annual Meeting 2023 that took place in Orlando, Florida. Dr. Tendler unveiled a scientific poster summarizing a year of progress in research and development.
The highlight of the presentation was ExoProTher's groundbreaking discovery: the efficacy of chicken p53 in combating human cancer. This result holds immense promise for innovative therapies and advances our understanding of cancer mechanisms. Presented results showcased successful outcomes across a variety of human cancer cell line in vitro, including GBM, colon, ovarian, and lung cancers.
"Our presence at AACR reaffirms ExoProTher's commitment to pushing medical boundaries," said Dr. Tendler. "The potential of chicken p53 in human cancer cells opens new doors in our fight against cancer."
Engaging with thought leaders across various fields, ExoProTher harnessed the AACR Annual Meeting to enrich its perspective and fuel future research endeavors.

ExoProTher takes part in JP Morgan week in San Francisco as part of Israeli Health Innovation Delegation organized by California Israel Chamber of Commerce (CICC).

The origin of our anti-cancer treatment - ExoProTher Medical on OutcomesRocket

30 seconds about the origin of our anti-cancer treatment.
https://youtu.be/IhR6-W6CM0E

ExoProTher is awarded a research grant and starting an exciting new collaboration with Dr. Mizied Falah

ExoProTher Medical : CTO Dr. Alex Tendler : Latest updates
Rosh-HaShanah : San Diego

Hosted by #Shay Wail

Video of the event:
https://lnkd.in/dFY86rMg

We are excited to step into 2022 together with IBF
https://israelbiotechfund.com/
Proud to be part of exclusive portfolio of innovative #lifesciences companies.
This funding accelerates the path towards clinical stage of our first-in-class biotherapy targeting cancers with p53 mutations.
We are on mission to bring cure to cancer patients.

This week ExoProTher Medical presented at the virtual MedInvest Oncology Investor Conference. ExoProTher’s Chief Executive Officer, Lana Volokh, delivered the corporate overview. She described the Company’s unique scientific foundation and technology and provided an update on program status. ExoProTher aims to significantly impact the way cancer is treated. Link to the presentation recording: https://youtu.be/JxwwiSTyrwk

Presenting our latest results at the PAT-ICRS workshop.

Investors event in our R&D Lab at Colab square Yokneam, taking a glimpse into the digital microscope along with markers on milestones achieved.

Beginning May 2021, ExoProTher is operating a new R&D lab situated at unique Colab Square facility in Yokneam Industrial park. ExoProTher is joining a line of exciting and promising biotech companies.

The combination of location, equipment and environment allow to boost R&D activities and attract top talent to the expanding team.

ExoProTher Medical - Co-founder & CEO Dr. Lana Volokh
at The Investor Forum - at the 2021 Virtual World Stem Cell Summit. (hosted by channelchek)

SEV2021 Annual Meeting
ExoProTher's scientific abstract reporting our recent preclinical results at the Annual Meeting of International Society for Extracellular Vesicles.

"Magic bullet against cancer"

​

Short Communication - Journal of Molecular Oncology Research (2021) Volume 5, Issue 2

ExoProTher article in Israeli business daily the "Globes".


Hebrew article by Globes' biomed reporter, Gali Weinreb.

ExoProTher is honored to be selected among top ten Israeli companies in the largest startup competition in the world - Startup World Cup.



Best regards,

Lana Volokh - CEO

I am pleased to share with our followers and investors the latest in vivo results.

​

Two weeks ago, a successful in vivo experiment on mouse model of colon cancer ended with impressive results. Life span of treated mice was significantly prolonged after single dose of Exo, while 25% of them remained tumor-free after the experiment completion. Additional in vivo studies using other cancer models are in progress.



Best regards,

Lana Volokh - CEO

Exciting growth period for ExoProTher Medical: we opened a new laboratory facility and brought on board new talent.



The new laboratory started functioning in Shlomi, Israel. It will focus on optimizing production and characterization of EXO_ compounds.



With extended R&D team, we continue to broaden and deepen our research capabilities.

Velocity on the rise not only in our labs.

Great boost coming from amazing crowd engagement in the SoCal startup event.

We are excited to attend the SoCal Startup Day and present our development.
Come see our quick-fire presentation as part of the start-up competition and visit us at booth #22 to learn more about our unique approach.

ExitValley and Eternity Capital investors event at the Tel-Aviv stock exchange.

ExoProTher VP Business Development update and call for action.

About a week into the campaign and the traction is high,

More than 100% of initial funding target.

What a great event to be part of – first ExitValley’s Investors meeting!

Dr. Alex Tendler, co-founder and CTO of ExoProTher Medical, presented our unique concept and its outstanding potential to the very interested audience.

​

Excellent traction,

ExoProTher Medical launched the crowdfunding campaign using ExitValley platform.


It is super cool to see first investment after less than 12 hours. Amazing start.

TheMarker's OncoTalk
publication
Harness evolution to fight cancer

OncoTalk's brief - exposing ExoProTher innovative approach

Exosomes fighting cancer